Skip to main content
. 2020 Nov;8(21):1389. doi: 10.21037/atm-20-3466

Figure 4.

Figure 4

Precision treatment of PRCC2 patient with next generation sequencing data. (A) Treatment response after 1cycle of bevacizumab with erlotinib treatment in patient with HLRCC (PRCC type 2); (B) treatment response after pazopanib in PRCC2 with somatic FH mutation; (C) treatment response after axitinib in PRCC2 with PBRM1 and SETD2 mutation. PRCC2, PRCC type 2.